You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors

 

Online download statistics by month:

Online download statistics by month: November 2021 to July 2025

AbstractFullPdf
Nov 202135723576851
Dec 2021794797236
Jan 2022698733233
Feb 2022426436118
Mar 202229530189
Apr 202229330486
May 202228028143
Jun 202221422049
Jul 202218818838
Aug 202221121226
Sep 2022270273109
Oct 202221321580
Nov 2022277277104
Dec 202211511638
Jan 2023919439
Feb 202310810823
Mar 202310510730
Apr 2023565611
May 2023676825
Jun 2023696919
Jul 2023525321
Aug 2023747413
Sep 2023717514
Oct 202314614719
Nov 202337938023
Dec 202324624838
Jan 2024909273
Feb 2024848520
Mar 2024959587
Apr 2024676927
May 2024818113
Jun 2024113112163
Jul 202412813345
Aug 2024464767
Sep 2024626227
Oct 2024777725
Nov 2024747530
Dec 202418418924
Jan 202511711725
Feb 202527627635
Mar 202510810830
Apr 202511211249
May 202511411447
Jun 2025313112
Jul 2025110
Total11170112843174